Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. develops and commercializes medicines for genetic conditions through a decentralized biopharmaceutical model. News for BBIO centers on Attruby/acoramidis, its oral transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM), including clinical data from ATTRibute-CM, commercial updates, Brazil marketing authorization under the BEYONTTRA name, and licensing or commercialization arrangements.
Company updates also cover late-stage genetic-disease programs such as encaleret for autosomal dominant hypocalcemia type 1, BBP-418 for limb-girdle muscular dystrophy type 2I/R9, and oral infigratinib for achondroplasia. Recurring financial and corporate items include quarterly results, product revenue trends, capital actions, employee equity inducement grants, investor conference participation, and pipeline regulatory disclosures.
BridgeBio (NASDAQ: BBIO) will present long-term efficacy and safety data from the ATTRibute-CM open-label extension (OLE) trial of acoramidis at the American College of Cardiology Annual Scientific Sessions in New Orleans on March 28-30, 2026.
A late-breaking oral presentation on survival and disease stabilization is scheduled for March 30 at 2:33 pm CT, plus three posters on biomarker, health-status and real-world survey findings on March 28 and March 30.
BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity awards approved March 18, 2026 for 29 new employees totaling 70,916 restricted stock units.
One-fourth of each award vests on February 16, 2027, then one-twelfth of the remainder vests quarterly thereafter, subject to continued employment. Awards were granted under the company Plan adopted November 2019 and amended February 10, 2023 and December 13, 2023, pursuant to Nasdaq Listing Rule 5635(c)(4).
BridgeBio (Nasdaq: BBIO) presented positive Phase 3 FORTIFY interim data for oral BBP-418 in LGMD2I/R9 showing rapid, consistent efficacy and a favorable safety profile.
Key results: 31-second 100MTT benefit at 12 months, CK reductions with 38.3% normalization, comparable serious adverse event rates, and an intended NDA submission in H1 2026.
BridgeBio (Nasdaq: BBIO) will present additional interim Phase 3 FORTIFY data for BBP-418 in LGMD2I/R9 at the MDA Clinical & Scientific Conference in Orlando, March 8-11, 2026. A late-breaking oral presentation on March 11 will report the interim analysis meeting efficacy endpoints; collaborators will deliver one oral talk and four posters.
BridgeBio (Nasdaq: BBIO) reported $154.2M in Q4 2025 revenue and $502.1M for full-year 2025, driven mainly by Attruby net product sales of $146.0M (Q4) and $362.4M (FY). The company announced three positive Phase 3 readouts and plans multiple NDAs in 1H/2H 2026 with U.S. launches anticipated in late 2026/early 2027. Cash, equivalents, and marketable securities totaled $587.5M at year-end; BridgeBio completed issuance of $632.5M 2033 convertible notes in Jan 2026 to support commercial and pipeline operations.
BridgeBio (Nasdaq: BBIO) announced that management will participate in three March 2026 healthcare investor conferences with scheduled fireside chats in Boston and Miami.
Presentations include TD Cowen on March 2, 2026 at 3:50 pm ET, Leerink Partners on March 10, 2026 at 1:00 pm ET, and Barclays on March 11, 2026 at 12:30 pm ET. Live webcasts and 90-day replays will be available on the company website.
BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity grants approved February 12, 2026, awarding 76,701 restricted stock units to 34 new employees.
One-fourth of each employee grant vests on February 16, 2027, then one-twelfth of the remainder vests quarterly thereafter, subject to continued employment. Grants were made under the company's Plan and Nasdaq Listing Rule 5635(c)(4).
BridgeBio (Nasdaq: BBIO) will report its fourth quarter and full year 2025 financial results and provide a business update after market close on February 24, 2026. The company will host a conference call and live webcast at 4:30 pm ET the same day. A replay will be available on the investor website for 30 days.
BridgeBio (Nasdaq: BBIO) reported positive Phase 3 PROPEL 3 topline results for oral infigratinib in children with achondroplasia. Key wins: AHV treatment difference +1.74 cm/year (LS mean), mean difference +2.10 cm/year; height Z‑score +0.41 SD; first statistically significant improvement in body proportionality in children 8 years.Oral infigratinib was well tolerated, with no drug‑related discontinuations and three mild, transient cases (4%) of hyperphosphatemia. NDA/MAA planned H2 2026; Breakthrough Therapy designation maintained.
BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity grants approved January 23, 2026, to 11 new employees totaling 31,428 restricted stock units.
One-fourth of each award vests on February 16, 2027, then one-twelfth of the remaining shares vests quarterly thereafter, subject to continued employment. Awards were granted under the Amended and Restated 2019 Inducement Equity Plan.